Northwire Canada EditionThursday, October 15, 2026
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Earnings Neutral

Light AI reports Financial Results for Three Months ended March 31, 2026

Pre-revenue diagnostics firm narrows losses but liquidity runway tightens ahead of commercial launch

Executive Summary
  • Light AI reported Q1 2026 financial results showing a net comprehensive loss of $2,062,424, an improvement from the $2.25 million loss in Q4 2025.
  • Cash position decreased to $4.6 million as of March 31, 2026, down from $6.5 million at year-end 2025.
  • Net working capital dropped significantly to approximately $3.7 million from $5.4 million in December 2025.
  • Commercialization for the QuickScan™ Strep A software is now planned for mid-2026, slightly accelerated from previous Q3-Q4 expectations.
  • R&D expenses decreased 40% year-over-year but increased 24% quarter-over-quarter due to recruiting costs in G&A.
  • Cash used in operating activities was $1.9 million during Q1 2026, down from $5.2 million in the prior year period.
Material Impact
  • The earnings release is not a material game changer as it does not introduce new financing or revenue streams.
  • Progress on commercialization timeline (mid-2026) is positive but incremental and expected by the market given previous guidance.
  • Liquidity metrics show deterioration; working capital decreased by $1.7 million in one quarter, raising concerns about runway sufficiency before revenue generation begins.
  • The slight improvement in net loss is routine for a pre-revenue company transitioning to commercialization and does not materially alter risk profile without confirmed sales.
  • No new strategic investors or major contracts were announced that would validate the business model beyond internal milestones.
ALGO · Price
Company Overview
  • Light AI Inc. develops an AI-powered diagnostic software platform for medical conditions using smartphone imaging.
  • Flagship product: QuickScan™ Strep A application, which detects Group A Streptococcus from smartphone images without swabs or lab tests.
  • Platform claims 96.57% overall accuracy and 100% Negative Predictive Value for distinguishing viral vs. bacterial pharyngitis (pre-FDA validation).
  • Strategic vision includes a cloud-based "Digital Clinical Lab" to reduce reliance on traditional lab infrastructure.
  • Company is transitioning from R&D phase to commercialization with Version 1.0 software completed in November 2025.
Read the original news release →

More from LIGHT AI INC.